Valuing Trial Designs from a Pharmaceutical Perspective Using Value-Based Pricing.

about

Estimating the Expected Value of Sample Information Using the Probabilistic Sensitivity Analysis Sample: A Fast, Nonparametric Regression-Based Method.

P2860

Q35752778-35D41DF1-0FAF-4414-8A2D-06D1544C4898

P2860

Valuing Trial Designs from a Pharmaceutical Perspective Using Value-Based Pricing.

Item

http://www.wikidata.org/entity/Q45930178

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

Valuing Trial Designs from a Pharmaceutical Perspective Using Value-Based Pricing.

@en

Valuing Trial Designs from a Pharmaceutical Perspective Using Value-Based Pricing.

@nl

type

Item

label

Valuing Trial Designs from a Pharmaceutical Perspective Using Value-Based Pricing.

@en

Valuing Trial Designs from a Pharmaceutical Perspective Using Value-Based Pricing.

@nl

prefLabel

Valuing Trial Designs from a Pharmaceutical Perspective Using Value-Based Pricing.

@en

Valuing Trial Designs from a Pharmaceutical Perspective Using Value-Based Pricing.

@nl

P1476

Valuing Trial Designs from a Pharmaceutical Perspective Using Value-Based Pricing.

@en

P2093

Penny Breeze

http://www.w3.org/2001/XMLSchema#string

P2860

The value of improving the productivity of the drug development process: faster times and better decisions

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

Estimating the cost of new drug development: is it really 802 million dollars?

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

Expected value of sample information for Weibull survival data.

Estimating expected value of sample information for incomplete data models using Bayesian approximation.

Operationalizing value-based pricing of medicines : a taxonomy of approaches.

Accounting for the drug life cycle and future drug prices in cost-effectiveness analysis.

Future drug prices and cost-effectiveness analyses.

Addressing adoption and research design decisions simultaneously: the role of value of sample information analysis.

P304

1468-1482

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEC.3103

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Alan Brennan

P577

2014-09-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

265514212

http://www.w3.org/2001/XMLSchema#string

P698

25204721

http://www.w3.org/2001/XMLSchema#string

Valuing Trial Designs from a Pharmaceutical Perspective Using Value-Based Pricing.

about

P2860

P2860

Valuing Trial Designs from a Pharmaceutical Perspective Using Value-Based Pricing.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698